Food & Drug Administration (FDA) approved the GLP-1 drug Wegovy to help reduce the risk of serious heart problems among people who are overweight or have obesity who do not necessarily have type 2 diabetes
Lee Rosebush #PeptideMedicine #FDA #503A #Compounding Thank you, AAPM for all your effort leading up to, and during the hearing
Monitoring for any changes in symptoms or side effects is important for adjusting medications if necessary
Patients with known hypersensitivity to peptides, those taking multiple medications with interaction potential, or individuals with significant medical comorbidities should start at 150-200mcg regardless of age to minimize complication risks
In 2022, Novartis underwent several changes to its corporate structure
This matters because compounded semaglutide users often experience variable GI tolerance, and alcohol compounds those effects unpredictably